Cologuard, Exact Sciences' stool DNA based colorectal cancer screen test, has new modeling data supporting a three-year testing interval.
The data, published in the journal Clinical Colorectal Cancer, supports the use of Cologuard every three years, in favorable comparison with using colonoscopy every 10 years.
"When a three-year Cologuard interval is modeled, Cologuard produces reductions in colon cancer incidence and related mortality similar to colonoscopy every 10 years. These significantly improved outcomes can be achieved at a reasonable cost for the millions of American who will not participate in colonoscopy screening, while providing less burden to patients, providers and health systems than annual screening," said Kevin Conroy, chairman and CEO of Exact Sciences.
The modeling also found Cologuard to be a cost-effective option; following a positive test, three-year stool DNA testing costs $11,313 per quality adjusted life year compared with no screening.